Literature DB >> 9820354

Bioavailability of oral ciprofloxacin in early postsurgical patients.

D J Hackam1, N Christou, Y Khaliq, D R Duffy, D Vaughan, J C Marshall, O D Rotstein.   

Abstract

OBJECTIVE: To evaluate the absorption of oral ciprofloxacin within 24 hours of laparotomy for major elective surgery or peritonitis.
DESIGN: In this prospective trial, patients were given a 750-mg oral close the morning after major elective surgery (n=15) or surgery for peritonitis (n=7). Healthy volunteers served as controls (n=9). Serial urine and blood samples were drawn during the subsequent 12 hours, and pharmacokinetic measures were determined by standard high-performance liquid chromatography assay procedures.
SETTING: Multicenter, university-affiliated hospitals. MAIN OUTCOME MEASURES: Drug absorption as determined by area under the concentration time curve, maximum concentration, and time to maximum concentration.
RESULTS: Oral bioavailability was reduced in elective surgery and peritonitis patients compared with controls. Among the 15 elective surgery patients, 27% (4/15) showed no absorption. The remaining 73% (11/15) had an area under the curve comparable with that of controls (8.3+/-1.6 (mg/[L x h]). Among all patients, those who showed drug absorption vs those who showed no absorption did not differ with respect to malignant neoplasm, case type, age, or biochemistry. However, patients showing no absorption were significantly heavier than patients showing absorption (patients showing absorption, 15%+/-3% over ideal body weight vs patients showing no absorption, 29%+/-6% over ideal body weight; P<.05). When elective surgery patients were stratified by presence or absence of obesity (25% above ideal body weight), mean area under the curve in nonobese patients was 9.80+/-2.37 vs 0.91+/-0.56 (mg/(L x h) in obese patients (P<.05).
CONCLUSIONS: Oral bioavailability was reduced for peritonitis surgery patients on the first day postoperatively, and for obese elective surgery patients. To achieve adequate serum levels requires continuation of intravenous antibiotics in patients with peritonitis, and adjustment of oral dosage in obese patients in the early period after elective surgery.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9820354     DOI: 10.1001/archsurg.133.11.1221

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  4 in total

1.  Risks of interrupting drug treatment before surgery.

Authors:  D W Noble; H Kehlet
Journal:  BMJ       Date:  2000-09-23

2.  Antistaphylococcal activities of the new fluoroquinolone JNJ-Q2.

Authors:  Brian J Morrow; Darren Abbanat; Ellen Z Baum; Steven M Crespo-Carbone; Todd A Davies; Wenping He; Wenchi Shang; Anne Marie Queenan; A Simon Lynch
Journal:  Antimicrob Agents Chemother       Date:  2011-09-12       Impact factor: 5.191

3.  Interrupting drug therapy in the perioperative period.

Authors:  David W Noble; John Webster
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 4.  A Physiologically-Based Pharmacokinetic Model to Describe Ciprofloxacin Pharmacokinetics Over the Entire Span of Life.

Authors:  Jan-Frederik Schlender; Donato Teutonico; Katrin Coboeken; Katrin Schnizler; Thomas Eissing; Stefan Willmann; Ulrich Jaehde; Heino Stass
Journal:  Clin Pharmacokinet       Date:  2018-12       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.